2016-06-24

At 11 am of June 24^th, 2016, Dr. Walter HU, Deputy Secretary General investigated the pharmaceutical industry of Saxony with the companionship of Mr. Hans-Jurgen Gross, Project Manager of Saxony Economic Development Corporation and Mr. Henrich Guntermann, CEO of European Consortium of Technology Transfer (ECTT) in Dresden. ECMDC Delegation had visited Arevipharma Company and Pharmapark Radebeul in succession.

ECMDC Delegation firstly visited Arevipharma Company. Ms. Barbel Starke, Project Manager warmly received the guest. According to the introduction, Saxony has the pharmaceutical history of more than 120 years and is consistently one of the most dynamic pharmaceutical bases in the field of life science in Germany. Arevipharma is the famous company with the history of more than 100 years and possesses the strong competency in R & D, manufacturing, and the rich store of patents.

Dr. Walter HU and Ms. Barbel Starke, Mr. Hans-Jurgen Gross, Mr. Henrich Guntermann

At the meeting, Dr. HU expounded the purpose of this visiting, which was to find German pharmaceutical technology partners for Chinese pharmaceutical companies. He said, there was a huge gap between Chinese pharmaceutical technology and German counterparts. Since pharmaceutical technology was directly concerned with the welfare of Chinese people, the Chinese government attached the great importance to the improvement of R & D of Chinese pharmaceutical companies. Therefore, ECMDC made the first step and selected the high-quality partner for Chinese companies. Ms. Barbel Starke said, Arevipharma, which was founded in 1874 had the strong R & D competency and the high-quality pharmaceutical technology and would surely be the ideal and trustworthy partner for Chinese friends.

Mr. Henrich Guntermann remarked that ECTT and ECMDC had established the good cooperation model. ECMDC would define the actual needs of Chinese clients and submitted the related information to ECTT that was responsible to provide the technical support and meet with the specific demands of Chinese partners. The cooperation had resulted in a successful case within a short period of time. Ms. Starke showed the great interest in this cooperation model. She said, it would be very necessary to have the third party who would facilitate the cooperation. Since ECMDC was the European NGO, the role it could play would be of vital importance. Dr. HU also presented the progress of EU-China Sci-Tech Financial Center of ECMDC. He said, many Chinese partners expected to participate in the construction of the creative platform of EU-China Sci-Tech Financial Center. While integrating the advanced European technology into the vast Chinese market, Chinese enterprises would like to invest in R & D in Europe as well through this platform in order to realize win-win.

Hans-Jurgen Gross said, Saxony had a remarkable industrial basis and R & D competency, which was ranked with very high placement in Germany. Saxony Government also encouraged the international cooperation and would provide the high-quality service. So, Chinese partners would surely achieve their designated commercial objectives in Saxony and the cooperation between Chinese partners and the excellent pharmaceutical company of Saxony, Arevipharma would be very satisfying and successful. Mr. Guntermann said, he would represent ECMDC to carry out the in-depth discussion with Ms. Starke as for the specific projects in various aspects.

After the meeting, ECMDC Delegation visited the pharmaceutical sci-tech innovation space of Arevipharma. According to Ms. Starke’s introduction, Arevipharma, the prestigious company with such a long history attached great attention to sci-tech innovation; henceforth, the company specially designated a building with the complete facilities to attract professionals to incubate their technologies here and create their start-up companies. To make the full use of the existing facilities in order to incubate the pharmaceutical technology would be a very cost-effective method, since it would cost a huge amount of money and take a long time to construct a new building with the full qualifications for laboratory R & D. The existing facilities and the rich store of professional knowledge of Arevipharma had attracted many pharmaceutical start-up companies or teams to settle down in this special building.

Pharmaceutical Sci-Tech Innovation Space of Arevipharma

ECMDC Delegation also visited Pharmapark Radebeul and investigated several cooperation projects.

When the field investigation of two days came to end, Dr. Walter HU discussed with Mr. Henrich Guntermann as for the future work. They had reached the consensus that both parties would actively promote the in-depth cooperation between Chinese enterprises and Saxony, and would have the preliminary assessment of the work of establishing EU-China (Dresden) Sci-Tech Financial Center and EU-China (Leipzig) Sci-Tech Financial Center with a view to enabling EU-China Sci-Tech Financial Center to become the platform and bridge that could facilitate the down-to-earth cooperation between Europe and China.